Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. (Record no. 28008562)

MARC details
000 -LEADER
fixed length control field 01484 a2200373 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250517195403.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201803s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1744-7607
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1080/17425255.2018.1432594
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Patti, Francesco
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20180309
245 00 - TITLE STATEMENT
Title Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Expert opinion on drug metabolism & toxicology
Date of publication, distribution, etc. Mar 2018
300 ## - PHYSICAL DESCRIPTION
Extent 341-352 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Journal Article; Review
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Animals
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal, Humanized
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Biological Availability
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Daclizumab
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Dose-Response Relationship, Drug
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunoglobulin G
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunosuppressive Agents
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Interleukin-2 Receptor alpha Subunit
General subdivision immunology
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Magnetic Resonance Imaging
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Medication Adherence
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Multiple Sclerosis, Relapsing-Remitting
General subdivision drug therapy
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Chisari, Clara G
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name D'Amico, Emanuele
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Zappia, Mario
773 0# - HOST ITEM ENTRY
Title Expert opinion on drug metabolism & toxicology
Related parts vol. 14
-- no. 3
-- p. 341-352
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1080/17425255.2018.1432594">https://doi.org/10.1080/17425255.2018.1432594</a>
Public note Available from publisher's website

No items available.